This module uses fundamental data of Repro Med to approximate the value of its Beneish M Score. Repro Med M Score tells investors if the company management is likely to be manipulating earnings. The score is calculated using eight financial indicators that are adjusted by a specific multiplier. Please note, the M Score is a probabilistic model and cannot detect companies that manipulate their earnings with 100% accuracy. Check out Repro Med Piotroski F Score and Repro Med Altman Z Score analysis.
Repro
Beneish M Score
Market Cap
Enterprise Value
Price To Sales Ratio
Dividend Yield
Ptb Ratio
Days Sales Outstanding
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Average Payables
Stock Based Compensation To Revenue
Capex To Depreciation
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Inventory Turnover
Net Income Per Share
Days Of Inventory On Hand
Payables Turnover
Average Inventory
Research And Ddevelopement To Revenue
Capex To Revenue
Cash Per Share
Pocfratio
Interest Coverage
Payout Ratio
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Intangibles To Total Assets
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Receivables Turnover
Graham Number
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Average Receivables
Revenue Per Share
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Operating Cycle
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Dividend Payout Ratio
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Long Term Debt To Capitalization
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Cash Conversion Cycle
Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding
Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Gross Profit Margin
Price Fair Value
Return On Equity
Sale Purchase Of Stock
Change To Inventory
Change In Cash
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Other Cashflows From Financing Activities
Depreciation
Dividends Paid
Capital Expenditures
Total Cash From Operating Activities
Change To Account Receivables
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Other Non Cash Items
Stock Based Compensation
Investments
Total Cashflows From Investing Activities
Change To Operating Activities
Other Cashflows From Investing Activities
Change To Netincome
Change To Liabilities
Net Borrowings
Issuance Of Capital Stock
Change Receivables
Cash And Cash Equivalents Changes
Cash Flows Other Operating
Total Assets
Short Long Term Debt Total
Total Current Liabilities
Net Debt
Retained Earnings
Cash
Non Current Assets Total
Non Currrent Assets Other
Net Receivables
Good Will
Common Stock Total Equity
Short Term Investments
Liabilities And Stockholders Equity
Non Current Liabilities Total
Inventory
Total Liab
Property Plant And Equipment Gross
Total Current Assets
Accumulated Other Comprehensive Income
Intangible Assets
Short Term Debt
Other Current Liab
Total Stockholder Equity
Property Plant And Equipment Net
Accounts Payable
Cash And Short Term Investments
Common Stock Shares Outstanding
Other Current Assets
Other Stockholder Equity
Common Stock
Current Deferred Revenue
Other Liab
Net Tangible Assets
Other Assets
Capital Surpluse
Treasury Stock
Property Plant Equipment
Net Invested Capital
Capital Stock
Net Working Capital
Capital Lease Obligations
Retained Earnings Total Equity
Depreciation And Amortization
Interest Expense
Total Revenue
Gross Profit
Other Operating Expenses
Operating Income
Ebit
Research Development
Ebitda
Cost Of Revenue
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Income Tax Expense
Selling General Administrative
Tax Provision
Interest Income
Net Income From Continuing Ops
Net Income Applicable To Common Shares
Net Interest Income
Reconciled Depreciation
Non Operating Income Net Other
Probability Of Bankruptcy
At present, Repro Med's Short Term Debt is projected to increase significantly based on the last few years of reporting. The current year's Short and Long Term Debt is expected to grow to about 335 K, whereas Long Term Debt Total is forecasted to decline to 2,120. At present, Repro Med's PTB Ratio is projected to slightly grow based on the last few years of reporting. The current year's Book Value Per Share is expected to grow to 0.47, whereas Days Sales Outstanding is forecasted to decline to 37.34.
At this time, it appears that Repro Med Systems is an unlikely manipulator. The earnings manipulation may begin if Repro Med's top management creates an artificial sense of financial success, forcing the stock price to be traded at a high price-earnings multiple than it should be. In general, excessive earnings management by Repro Med executives may lead to removing some of the operating profits from subsequent periods to inflate earnings in the following periods. This way, the manipulation of Repro Med's earnings can lead to misrepresentations of actual financial condition, taking the otherwise loyal stakeholders on to the path of questionable ethical practices and plain fraud.
The cure to earnings manipulation is the transparency of financial reporting. It will typically remove the temptation of the top executives to inflate earnings (i.e., to promote the idea of 'winning at any cost'). Because a healthy internal audit department can enhance transparency, the board should promote the auditors' access to all the record-keeping systems across the enterprise. For example, if Repro Med's auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back.
One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to detect the potential manipulation of earnings. Understanding the correlation between Repro Med's different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Repro Med in a much-optimized way. Analyzing correlations between earnings drivers directly associated with dollar figures is the most effective way to find Repro Med's degree of accounting gimmicks and manipulations.
M-Score is one of many grading techniques for value stocks. It was developed by Professor M. Daniel Beneish of the Kelley School of Business at Indiana University and published in 1999 under the paper titled The Detection of Earnings Manipulation. The Beneish score is a multi-factor model that utilizes financial identifiers to compile eight variables used to classify whether a company has manipulated its reported earnings. The variables are built from the officially filed financial statements to create a final score call 'M Score.' The score helps to identify companies that are likely to manipulate their profits if they show deteriorating gross margins, operating expenses, and leverage against growing revenue.
Depreciation And Amortization
913,910
At present, Repro Med's Depreciation And Amortization is projected to increase significantly based on the last few years of reporting.
Repro Med Earnings Manipulation Drivers
Although earnings manipulation is typically not the result of intentional misconduct by the c-level executives, it is still a widespread practice by the senior management of public companies such as Repro Med. It is usually done by a series of misrepresentations of various accounting rules and operating activities across multiple financial cycles. The best way to spot the manipulation is to examine the historical financial statement to find inconsistencies in earning reports to find trends in assets or liabilities that are not sustainable in the future.
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Repro Med's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Repro Med's managers, analysts, and investors.
Environmental
Governance
Social
About Repro Med Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Repro Med Systems's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Repro Med using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Repro Med Systems based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Repro Med Systems is a strong investment it is important to analyze Repro Med's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Repro Med's future performance. For an informed investment choice regarding Repro Stock, refer to the following important reports:
You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Repro Med. If investors know Repro will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Repro Med listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.66)
Earnings Share
(0.26)
Revenue Per Share
0.674
Quarterly Revenue Growth
0.215
Return On Assets
(0.14)
The market value of Repro Med Systems is measured differently than its book value, which is the value of Repro that is recorded on the company's balance sheet. Investors also form their own opinion of Repro Med's value that differs from its market value or its book value, called intrinsic value, which is Repro Med's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Repro Med's market value can be influenced by many factors that don't directly affect Repro Med's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Repro Med's value and its price as these two are different measures arrived at by different means. Investors typically determine if Repro Med is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Repro Med's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.